Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227025 · ClinicalTrials.gov registry record · Phase 1

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
16
Study locations

NCT07227025 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 60 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227025, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
16
Study locations

Study Summary

The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Olomorasib
  • DRUG Amivantamab

Study Locations (16)

Other

  • The First Affiliated Hospital Sun Yat sen University - Guangzhou
  • Shanghai East Hospital - Shanghai
  • Severance Hospital Yonsei University Health System - Seoul
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi - Ankara
  • Ankara Bilkent Sehir Hastanesi - Çankaya
  • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi - Istanbul

California

  • University of California Irvine - Irvine

Maine

  • New England Cancer Specialists - Topsham

New York

  • New York University Langone Medical Center - New York

Pennsylvania

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine - Philadelphia

Texas

  • Oncology Consultants Cancer Center - Houston

Virginia

  • Virginia Cancer Specialists - Fairfax

Washington

  • NorthWest Medical Specialties, PLLC - Puyallup

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-03-03
Est. Completion 2029-04-30
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07227025

The ClinicalTrials.gov registry entry for NCT07227025 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (81% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Olomorasib is the first listed.

NCT07227025 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Maine.

Frequently Asked Questions

What is clinical trial NCT07227025 about?

NCT07227025 is a clinical study titled "A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer". The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic ...

What is the current status of trial NCT07227025?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-03-03. Estimated completion is 2029-04-30.

What conditions does trial NCT07227025 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT07227025?

The interventions under investigation include: Olomorasib (DRUG), Amivantamab (DRUG).

Who is sponsoring clinical trial NCT07227025?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227025 being conducted?

This trial has 16 study locations across California, Maine, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.